Eli Lilly and Company (LLY) 12-Month Stock Forecast & Price Target Cone
$1,373.70 +6.63% NYSE • Public Delayed / 60s Snapshot
Eli Lilly and Company (LLY) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (84% profit margin, 32% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
ROARABLE B • BUY
Cap $1.33T
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw B+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+23% Base Target
WHALE OPTIONS TUG-OF-WAR:45% Call Buyers ($5.4M)
55% PutsMax Pain: $1,200.00
INTERACTIVE 12-MONTH POSITION SIMULATOR
Drag to Test Your LLY Position Size: $10,000
Shares at $1,373.70: 7.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $1,472.90
$10,722
+$722 (+7.2%)
12M Consensus BaseTarget $1,689.78
$12,301
+$2,301 (+23.0%)
12M Bull Case BreakoutTarget $1,824.45
$13,281
+$3,281 (+32.8%)
Wall Street Analyst Breakdown & Historical Accuracy Audit (36 Desks)
Street Historical Accuracy: 82/100● Strong Buy / Buy: 31● Hold: 4● Sell: 1
| Wall Street Firm | Stance | 12M Target | 1Y Accuracy | Track Grade |
|---|---|---|---|---|
| UBSAJ Rice | OUTPERFORM | $1,586 | 96% | A+ |
| JefferiesAkash Tewari | OUTPERFORM | $1,654 | 96% | A+ |
| CitigroupPeter Verdult | STRONG BUY | $1,708 | 93.2% | A+ |
| Bernstein SocGen GroupCourtney Breen / Lance Wilkes | OUTPERFORM | $1,637 | 89.7% | A+ |
| Morgan StanleyTerence Flynn | STRONG BUY | $1,785 | 85.2% | A |
| Evercore ISIUmer Raffat | STRONG BUY | $1,765 | 84.9% | A |
| Bank of America SecuritiesTim Anderson / Kevin Fischbeck | STRONG BUY | $1,799 | 82.6% | A |
| J.P. MorganChris Schott / Lisa Gill | OUTPERFORM | $1,666 | 79.3% | A |
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher + Senior Cash-Flow & Income Strategist
Cash-Fortress Compounders: Collecting Safe Yield & Upside in LLY & Top A-Rated Leaders
- ✓12-month Bull/Base/Bear fair-value walkthrough on LLY and its top sector rival
- ✓The Top 5 Roarable A-Rated cash compounders with heavy executive & 13F accumulation
- ✓Includes free daily Morning Market Weather & signal upgrade/downgrade dispatch
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
LLY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +47.15%▲ RESISTANCE BREAKOUT
2026-10-30O $1,286.4H $1,449.7L $1,260.3C $1,417.5VOL 15.63M
RES: $1,364.7SMA50: $1,197.1SMA200: $1,091.2
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LLY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
-0.53% YoY Shares
SEC XBRL FY2024 → FY2025: Net share cannibal / buyback tailwind.
Reverse-DCF Expectations Hurdle (#30)
35.5%/yr Implied 5Y Growth
vs. +45.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
DEVELOPING · Incretin Capacity Base Reclaim
Trigger: $1452.98 • Invalidation: $1349.50
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
WST → LLY Confirmed Filing
West Pharmaceutical Services manufactures NovaPure fluoropolymer-coated elastomer plungers and cartridge seals required inside sterile single-dose and multi-dose GLP-1 auto-injector pens.
TMO → LLY Confirmed Filing
Following Novo Holdings acquisition of Catalent fill-finish sites, Eli Lilly and rival GLP-1 developers increasingly rely on Thermo Fisher Patheon sterile fill-finish lines to clear injectable pen bottlenecks.
LLY → NVO Confirmed Filing
Eli Lilly dual GIP/GLP-1 agonist tirzepatide (Zepbound/Mounjaro) demonstrated superior head-to-head weight loss vs. Novo Nordisk semaglutide (Wegovy) in SURMOUNT-5, intensifying PBM rebate competition.
AI Analyst Theses, Washington Policy & Company Video
💡 Friday Evidence Audit: What Confirmed, What Stalled & Where Options Overpriced the Move (felix-orven)
💡 Starter Kit: Cash-Fortress Zero-Dilution Compounders (ellis-vennor)
🏛️ COMMENT_RULEMAKING: CMS Contract Year Medicare Advantage Capitation Benchmark & Part D GLP-1 Coverage Rulemaking (Centers for Medicare & Medicaid Services (HHS — 42 CFR Parts 422 & 423))
🎬 No recent verified company-specific video clip queued for LLY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
LLY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is LLY's 12-month stock price target?
Eli Lilly and Company (LLY) carries a 12-month consensus base price target of $1689.78 (+23% from $1373.70), with a bull-case target of $1824.45 and a bear-case floor of $1472.9.
Is LLY stock a Buy, Hold, or Sell right now?
Roarable's 5-Pillar RQD Quant Engine rates LLY B (Buy — BUY) with an RQD Confidence score of 72/100.